Can Cellcept (mycophenolate mophetil) cause macular degeneration, cataract or other ocular side eff
Fråga: Can Cellcept (mycophenolate mophetil) cause macular degeneration, cataract or other ocular side effects?
The question concerns a 68-year-old female kidney transplant recipient treated with Cellcept and cortisone in therapeutic doses as immunosuppressants. After more than six months treatment the patient developed visual impairment, which was diagnosed as cataract and macular degeneration. Cellcept has been withdrawn but the visual impairment has not subsided. The physician believes that the macular degeneration is probably age related and that the cataract can be related to the cortisone treatment, but wants to be sure.
Sammanfattning: Occasional case reports of macular abnormalities, cataract and other untoward ocular effects of mycophenolate treatment have been reported in the literature. However, in a clinical study where mycophenolic acid was used in inflammatory eye diseases and in other studies on heart or renal recipients treated with mycophenolate no ocular side effects were observed. Cataract is also a well known side effect of cortisone treatment.
Svar: Oral therapy with high doses (up to 7g daily and mean dose 3g daily) of mycophenolic acid in psoriasis patients has been associated with ocular changes, including nuclear sclerotic cataracts, blepharitis, keratitis, glaucoma and macular abnormalities (1). These complications have not been reported in heart or renal transplant recipients treated with mycophenolate (2).
Eleven patients with ocular inflammation was included in an open-label, prospective uncontrolled study of mycophenolic acid as immunosuppressive treatment (3). One g mycophenolate mofetil was given twice daily in conjunction with steroids, or as an additional agent with cyclosporine, or instead of cyclosporine or azathioprine. Addition of mycophenolate led to improvement in symptom in ten of eleven patients, with few and no ocular side effects noted.
No cases of ocular side effects have been reported for mycophenolic acid to SADRAC (The Swedish Adverse Drug Reactions Advisory Committee). The WHO adverse drug reactions monitoring centre in Uppsala has received reports of a total of 31 cases of ocular side effects associated with mycophenolate treatment (4). Four of these reports concern cataract and one concerns macular degeneration. These reports are not all evaluated due to differences among reporting countries.
According to the manufacturer, cataract but not macular degeneration is listed, as a side effect in their files (5).
Cataract is a well-known side effect of cortisone treatment (6). 1 Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17:962-71. 2 Schweizer RT, Meisterling LD. Tolerability of mycophenolate mofetil in organ transplant recipients. Transplant Proc 2001;33:2309. 3 Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106:370-4. 4 Intdis (International Drug Information System): WHO:s adverse drug reactions database Mycophenolic acid. Adverse reactions to drugs. (2002-11-08) 5 Personal communication Birgitta Lilja, Roche AB (2002-11-12) 6 Grant WM, Schuman JS. Toxicology of the eye. Vol I. 4th ed. Springfield: Charles C Thomas Publisher; 1993. p. 22.
Referenser: